Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury

Kidney International

Volumn 80, Issue 5, 2011, Pages 524-534

  Bao, Lihua ^a   Wang, Ying ^a   Haas, Mark ^b   Quigg, Richard J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Cedars Sinai Medical Center   (United States)

Author keywords

Complement; Interstitial fibrosis; Renal failure; Transgenic mouse; Transplantation

Indexed keywords

CD11B ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT RECEPTOR; F4 80 ANTIGEN; THY 1 ANTIGEN; THY 1.2 ANTIGEN; UNCLASSIFIED DRUG; COMPLEMENT; COMPLEMENT COMPONENT C5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY FIBROSIS; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; FIBROSIS; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CHEMOTAXIS, LEUKOCYTE; COMPLEMENT C3A; COMPLEMENT C5; COMPLEMENT SYSTEM PROTEINS; FIBROSIS; MICE; NEPHRITIS, INTERSTITIAL; RENAL INSUFFICIENCY; SIGNAL TRANSDUCTION;

EID: 84863010724     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.158     Document Type: Article

References (55)

1. Walport MJ. Advances in immunology: complement (first of two parts). N Engl J Med 2001; 344: 1058-1066. (Pubitemid 32267977)
2. Kim Y-U, Kinoshita T, Molina H et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med 1995; 181: 151-159.
3. Xu C, Mao D, Holers VM et al. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science 2000; 287: 498-501.
4. Bao L, Wang Y, Chang A et al. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol 2007; 18: 811-822. (Pubitemid 46434498)
5. Renner B, Coleman K, Goldberg R et al. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol 2010; 185: 3086-3094.
6. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 2: 363-366.
7. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kid Dis 1992; 20: 1-17.
8. Klos A, Tenner AJ, Johswich KO et al. The role of the anaphylatoxins in health and disease. Mol Immunol 2009; 46: 2753-2766.
9. Martin U, Bock D, Arseniev L et al. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J Exp Med 1997; 186: 199-207. (Pubitemid 27328020)
10. Chenoweth DE, Hugli TE. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978; 75: 3943-3947. (Pubitemid 8399847)
11. Werfel T, Oppermann M, Schulze M et al. Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 1992; 79: 152-160.
12. Nataf S, Davoust N, Ames RS et al. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999; 162: 4018-4023. (Pubitemid 29314783)
13. Werfel T, Kirchhoff K, Wittmann M et al. Activated human T lymphocytes express a functional C3a receptor. J Immunol 2000; 165: 6599-6605.
14. Daffern PJ, Pfeifer PH, Ember JA et al. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995; 181: 2119-2127.
15. DiScipio RG, Daffern PJ, Jagels MA et al. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 1999; 162: 1127-1136. (Pubitemid 29035444)
16. Nilsson G, Johnell M, Hammer CH et al. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996; 157: 1693-1698. (Pubitemid 126449112)
17. Marder SR, Chenoweth DE, Goldstein IM et al. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol 1985; 134: 3325-3331. (Pubitemid 15246474)
18. Strey CW, Markiewski M, Mastellos D et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 2003; 198: 913-923. (Pubitemid 37152928)
19. Drouin SM, Corry DB, Hollman TJ et al. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002; 169: 5926-5933. (Pubitemid 35291699)
20. Strainic MG, Liu J, Huang D et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008; 28: 425-435.
21. Rosas M, Thomas B, Stacey M et al. The myeloid 7/4-antigen defines recently generated inflammatory macrophages and is synonymous with Ly-6B. J Leukoc Biol 2010; 88: 169-180.
22. Lagasse E, Weissman IL. Flow cytometric identification of murine neutrophils and monocytes. J Immunol Methods 1996; 197: 139-150. (Pubitemid 26342018)
23. Soos TJ, Sims TN, Barisoni L et al. CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int 2006; 70: 591-596. (Pubitemid 44141588)
24. Taylor PR, Brown GD, Geldhof AB et al. Pattern recognition receptors and differentiation antigens define murine myeloid cell heterogeneity ex vivo. Eur J Immunol 2003; 33: 2090-2097. (Pubitemid 37010025)
25. Martin WJ, Walton M, Harper J. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum 2009; 60: 281-289.
26. Tang Z, Lu B, Hatch E et al. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol 2009; 20: 593-603.
27. Thurman JM, Lenderink AM, Royer PA et al. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol 2007; 178: 1819-1828. (Pubitemid 46154654)
28. Boor P, Konieczny A, Villa L et al. Complement C5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol 2007; 18: 1508-1515. (Pubitemid 46717517)
29. Sacks SH. Complement fragments C3a and C5a: the salt and pepper of the immune response. Eur J Immunol 2010; 40: 668-670.
30. Melendi GA, Hoffman SJ, Karron RA et al. C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. J Virol 2007; 81: 991-999. (Pubitemid 46067923)
31. Kildsgaard J, Hollmann TJ, Matthews KW et al. Targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol 2000; 165: 5406-5409.
32. Hollmann TJ, Mueller-Ortiz SL, Braun MC et al. Disruption of the C5a receptor gene increases resistance to acute Gram-negative bacteremia and endotoxic shock: opposing roles of C3a and C5a. Mol Immunol 2008; 45: 1907-1915.
33. Wenderfer SE, Ke B, Hollmann TJ et al. C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice. J Am Soc Nephrol 2005; 16: 3572-3582. (Pubitemid 46211278)
34. Wenderfer SE, Wang H, Ke B et al. C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse. Mol Immunol 2009; 46: 1397-1404.
35. Humbles AA, Lu B, Nilsson CA et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000; 406: 998-1001.
36. Kohl J, Baelder R, Lewkowich IP et al. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest 2006; 116: 783-796. (Pubitemid 43326888)
37. Baelder R, Fuchs B, Bautsch W et al. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol 2005; 174: 783-789. (Pubitemid 40094273)
38. Zhang X, Lewkowich IP, Kohl G et al. A protective role for C5a in the development of allergic asthma associated with altered levels of B7-H1 and B7-DC on plasmacytoid dendritic cells. J Immunol 2009; 182: 5123-5130.
39. Niedermeier M, Reich B, Rodriguez GM et al. CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc Natl Acad Sci USA 2009; 106: 17892-17897.
40. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000; 11: 152-176. (Pubitemid 30020438)
41. Segerer S, Schlondorff D. Role of chemokines for the localization of leukocyte subsets in the kidney. Semin Nephrol 2007; 27: 260-274. (Pubitemid 46802915)
42. Kitagawa K, Wada T, Furuichi K et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004; 165: 237-246. (Pubitemid 38821831)
43. Marks RM, Todd III RF, Ward PA. Rapid induction of neutrophilendothelial adhesion by endothelial complement fixation. Nature 1989; 339: 314-317.
44. Ross GD, Vetvicka V. CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Exp Immunol 1993; 92: 181-184. (Pubitemid 23151023)
45. Wright SD, Griffin Jr FM. Activation of phagocytic cells' C3 receptors for phagocytosis. J Leukoc Biol 1985; 38: 327-339. (Pubitemid 15243434)
46. Schymeinsky J, Mocsai A, Walzog B. Neutrophil activation via beta2 integrins (CD11/CD18): molecular mechanisms and clinical implications. Thromb Haemost 2007; 98: 262-273. (Pubitemid 47260290)
47. Chen NJ, Mirtsos C, Suh D et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 2007; 446: 203-207. (Pubitemid 46398661)
48. He S, Atkinson C, Qiao F et al. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest 2009; 119: 2304-2316.
49. Mao D, Wu X, Deppong C et al. Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity 2003; 19: 813-822. (Pubitemid 37542302)
50. Hopken UE, Lu B, Gerard NP et al. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 1996; 383: 86-89. (Pubitemid 26296466)
51. Cunningham PN, Wang Y, Guo R et al. Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J Immunol 2004; 172: 2629-2635. (Pubitemid 38182415)
52. Bao L, Haas M, Boackle SA et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002; 168: 3601-3607. (Pubitemid 34250431)
53. Nomura A, Nishikawa K, Yuzawa Y et al. Tubulointerstitial injury induced in rats by a monoclonal antibody which inhibits function of a membrane inhibitor of complement. J Clin Invest 1995; 96: 2348-2356.
54. Bao L, Osawe I, Haas M et al. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 2005; 175: 1947-1955. (Pubitemid 41023102)
55. Bao L, Haas M, Pippin J et al. Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells. J Clin Invest 2009; 119: 1264-1274.